The data highlight the three drug candidates' potential for clinical development and promising synergistic utilities in new indications
WuXi Bio provided technical services, based on the companies' versatile integrated service platforms, to support various manufacturing and process development activities of these ADC product candidates.
The meeting provides recommendations to the G20 and its Member States and international partners on the establishment of a R&D and manufacturing network for diagnostics
Prometheus Biosciences’ comprehensive data set enables target discovery and precision medicine approach in inflammation and immunology
The combination will support clients in getting their end-to-end discovery and development programs delivered.
Acquisition positions Chiesi to expand patient access to approved treatments and advance efforts to develop new treatments for people living with rare diseases.
Calibre will enhance the pace of new product development and the breadth of its Custom Development and Manufacturing (CDMO) Service offerings.
Envelta is the company’s non-opioid pain product candidate for acute and chronic pain
FDA’s NME approvals declined substantially in 2022, causing overall New Drug Application (NDA) approvals to drop
Subscribe To Our Newsletter & Stay Updated
